TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06716606: An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD)

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 514 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,173,128

Rescue Site Savings

+$7,354,464

Unlock Full NCT06716606 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06716606 Rescue Dossier →